Overall market sentiment has been neutral on Kura Oncology Inc (KURA) stock lately. KURA receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.
Kura Oncology Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on KURA!
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With KURA Stock Today?
Kura Oncology Inc (KURA) stock is trading at $12.46 as of 4:00 PM on Tuesday, May 17, a rise of $0.87, or 7.51% from the previous closing price of $11.59. The stock has traded between $11.74 and $12.55 so far today. Volume today is 460,087 compared to average volume of 568,453.
To screen for more stocks like Kura Oncology Inc click here.
More About Kura Oncology Inc
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.
Click Here to get the full Stock Report for Kura Oncology Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter